5400 Carillon Point
Building 5000 4th Floor
Mavupharma is a drug discovery and development company focused on novel approaches to selectively targeting the STING pathway, leveraging the innate immune system to treat cancer and infectious diseases. Mavupharma recently completed a $20 million Series A financing led by Frazier Healthcare Partners.
President: Michael Gallatin, Ph.D.
CSO: Greg Dietsch, Ph.D., DABT
COO: Clayton D. Knox, M.D.
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.